Tags

Type your tag names separated by a space and hit enter

[Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)].
Przegl Lek. 2000; 57(1):59-64.PL

Abstract

Transdermal Fentanyl (TF, Durogesic) is a strong opioid analgesic which is used in the treatment of cancer pain. In this article we described basic properties and dosing guidelines for TF and our own experience with use of Durogesic in the treatment of cancer pain. In this open study TF was administered in 16 pts aged of 30-88 (mean 62 +/- 17) years with advanced cancer who suffered from strong cancer pain and who had previously been treated with morphine (11 pts), buprenorphine (1 pt), tramadol (2 pts) and non-opioid analgesics (2 pts). Analgesic efficacy and side-effects of TF were appraised. The time of the treatment was 7-235 (mean 77 +/- 58) days, the dose range 25-600 (mean 129 +/- 117) micrograms/h. The mean initial dose of Durogesic was 94 +/- 99 micrograms/h and the final dose of fentanyl patch was 156 +/- 149 micrograms/h. Good analgesic effect was achieved in 11 pts (69%), partial effect in 2 pts (12%), unsatisfactory analgesia in 3 pts (19%). The treatment was well tolerated and the most frequent adverse reactions were constipation in 10 pts (63%) and drowsiness in 4 pts (25%). During the therapy with TF we didn't encounter serious side-effects which would cause cessation of the treatment. Results of our study confirmed that TF was an effective analgesic most commonly used in pts with stable nociceptive pain especially when opioid analgesics could not be administered orally.

Authors+Show Affiliations

Klinika Opieki Paliatywnej, Anestezjologii i Intensywnej Terapii Onkologicznej, Katedra Onkologii Akademii Medycznej im. Karola Marcinkowskiego w Poznaniu.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article

Language

pol

PubMed ID

10907375

Citation

Leppert, W, et al. "[Research From the Palliative Care Department in Poznań On Treatment of Neoplasm Pain With Durogesic (transdermal Fentanyl)]." Przeglad Lekarski, vol. 57, no. 1, 2000, pp. 59-64.
Leppert W, Luczak J, Gorzelińska L, et al. [Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)]. Przegl Lek. 2000;57(1):59-64.
Leppert, W., Luczak, J., Gorzelińska, L., & Kozikowska, J. (2000). [Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)]. Przeglad Lekarski, 57(1), 59-64.
Leppert W, et al. [Research From the Palliative Care Department in Poznań On Treatment of Neoplasm Pain With Durogesic (transdermal Fentanyl)]. Przegl Lek. 2000;57(1):59-64. PubMed PMID: 10907375.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)]. AU - Leppert,W, AU - Luczak,J, AU - Gorzelińska,L, AU - Kozikowska,J, PY - 2000/7/25/pubmed PY - 2000/10/14/medline PY - 2000/7/25/entrez SP - 59 EP - 64 JF - Przeglad lekarski JO - Przegl Lek VL - 57 IS - 1 N2 - Transdermal Fentanyl (TF, Durogesic) is a strong opioid analgesic which is used in the treatment of cancer pain. In this article we described basic properties and dosing guidelines for TF and our own experience with use of Durogesic in the treatment of cancer pain. In this open study TF was administered in 16 pts aged of 30-88 (mean 62 +/- 17) years with advanced cancer who suffered from strong cancer pain and who had previously been treated with morphine (11 pts), buprenorphine (1 pt), tramadol (2 pts) and non-opioid analgesics (2 pts). Analgesic efficacy and side-effects of TF were appraised. The time of the treatment was 7-235 (mean 77 +/- 58) days, the dose range 25-600 (mean 129 +/- 117) micrograms/h. The mean initial dose of Durogesic was 94 +/- 99 micrograms/h and the final dose of fentanyl patch was 156 +/- 149 micrograms/h. Good analgesic effect was achieved in 11 pts (69%), partial effect in 2 pts (12%), unsatisfactory analgesia in 3 pts (19%). The treatment was well tolerated and the most frequent adverse reactions were constipation in 10 pts (63%) and drowsiness in 4 pts (25%). During the therapy with TF we didn't encounter serious side-effects which would cause cessation of the treatment. Results of our study confirmed that TF was an effective analgesic most commonly used in pts with stable nociceptive pain especially when opioid analgesics could not be administered orally. SN - 0033-2240 UR - https://www.unboundmedicine.com/medline/citation/10907375/[Research_from_the_Palliative_Care_Department_in_Poznań_on_treatment_of_neoplasm_pain_with_Durogesic__transdermal_fentanyl_]_ L2 - https://medlineplus.gov/pain.html DB - PRIME DP - Unbound Medicine ER -